India's Sovaldi patent rejection: what now and next?
This article was originally published in Scrip
Executive Summary
India's rejection of one of Gilead's key patent applications for hepatitis C treatment, Sovaldi (sofosbuvir), has thrown up many interesting potential prospects, as well as possible difficulties.